Overview

Individualizing Pharmacotherapy for African American Smokers

Status:
Active, not recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
Improving cessation outcomes for African American smokers through the use of novel, empirically-based strategies is a national health priority. In the vast majority of smoking cessation studies and in clinical practice, when smokers are provided a medication to help them quit, they are expected to continue that medication regardless of how well it is working. This study will assess whether African Americans smokers respond better if they continue with a single treatment or if their treatment is changed when that treatment is not working.
Phase:
Phase 3
Details
Lead Sponsor:
University of Kansas Medical Center
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Bupropion
Nicotine
Varenicline